Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2024

21-02-2024 | Adrenocortical Carcinoma | REVIEW

Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma

Authors: Chulkue Pak, Shinkyo Yoon, Jae Lyun Lee, Tak Yun, Inkeun Park

Published in: Current Oncology Reports | Issue 4/2024

Login to get access

Abstract

Purpose of Review

To provide a comprehensive overview of the current understanding and developments in the treatment options for adrenocortical carcinoma (ACC), focusing on the strategies utilized for advanced disease.

Recent Findings

Research has delved into the genomic landscape of ACC, revealing potential targets for therapy. Despite the failure of inhibitors aimed at the insulin like growth factor 1(IGF-1) receptor, other approaches, including vascular endothelial growth factor receptor (VEFGR) tyrosine kinase inhibitors and immune checkpoint inhibitors, are being investigated. There are also ongoing trials of combination treatments such as lenvatinib with pembrolizumab and cabozantinib with atezolizumab.

Summary

ACC remains a challenging malignancy with limited effective treatment options. Although EDP-M stands as the frontline treatment, the search for effective second-line therapies is ongoing. Targeted therapies and immunotherapies, especially in combination regimens, are demonstrating potential and are the subject of continued research. The evolving genomic landscape emphasizes the significance of targeted therapies and the need for further in-depth studies to solidify effective treatment regimens for ACC.
Literature
1.
Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579–86.PubMedCrossRef
2.
Vanbrabant T, Fassnacht M, Assie G, Dekkers O. Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. Eur J Endocrinol. 2018;179:429–36.PubMedCrossRef
3.
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.PubMedCrossRef
4.
Glenn JA, Else T, Hughes DT, Cohen MS, Jolly S, Giordano TJ, Worden FP, Gauger PG, Hammer GD, Miller BS. Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery. 2019;165:186–95.PubMedCrossRef
5.
•• Fassnacht M, Assie G, Baudin E, Eisenhofer G, De La Fouchardiere C, Haak H, De Krijger R, Porpiglia F, Terzolo M, Berruti A. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476–90.This is a latest clinical practice guidelines for diagnosis and treatment of ACC.PubMedCrossRef
6.
Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713–9.PubMedCrossRef
7.
Elhassan YS, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, Kastelan D, Fragoso M, Bertherat J, Al Ghuzlan A, Haak H, Boudina M, Canu L, Loli P, Sherlock M, Kimpel O, Lagana M, Sitch AJ, Kroiss M, Arlt W, Terzolo M, Berruti A, Deeks JJ, Libe R, Fassnacht M, Ronchi CL. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. Eur J Endocrinol. 2021;186:25–36. https://​doi.​org/​10.​1530/​EJE-21-0510.CrossRefPubMedPubMedCentral
8.
Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E, network E. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26:2119–25. https://​doi.​org/​10.​1093/​annonc/​mdv329.CrossRefPubMed
9.
Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100:841–9.PubMedCrossRef
10.
Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162:521–31.PubMedPubMedCentralCrossRef
11.
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré A-M, René-Corail F, Jullian E, Gicquel C, Bertagna X. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Can Res. 2005;65:7622–7.CrossRef
12.
Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723–36.PubMedPubMedCentralCrossRef
13.
Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, Rene-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libe R, de Reynies A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–12. https://​doi.​org/​10.​1038/​ng.​2953.CrossRefPubMed
14.
15.
16.
Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M. Mitotane inhibits Sterol-O-Acyl Transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895–908. https://​doi.​org/​10.​1210/​en.​2015-1367.CrossRefPubMed
17.
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.PubMedCrossRef
18.
Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023;11:720–30.PubMedPubMedCentralCrossRef
19.
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, De Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1–46.PubMedCrossRef
20.
Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J. Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug. Oncologist. 2017;22:1102–6.PubMedPubMedCentralCrossRef
21.
22.
Kerkhofs T, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller H, Skogseid B, Leboulleux S, Mantero F, Haak H. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759–67.PubMedCrossRef
23.
Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M. Plasma concentrations of o, p′ DDD, o, p′ DDA, and o, p′ DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@ T multicenter study. J Clin Endocrinol Metab. 2011;96:1844–51.PubMedCrossRef
24.
Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Altieri B, Della Casa S, Loli P, Pivonello R, De Martino MC, Canu L, Russo M, Badalamenti G, Torlontano M, Stigliano A, Ferraù F, Arnaldi G, Saba L, Quirino A, Perotti P, Berchialla P, Terzolo M. Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers. 2020;12:740.PubMedPubMedCentralCrossRef
25.
Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M. Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p′ DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385–92.PubMedCrossRef
26.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.PubMedCrossRef
27.
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445–53. https://​doi.​org/​10.​1677/​erc-09-0281.CrossRefPubMed
28.
Creemers S, Van Koetsveld P, Van Den Dungen E, Korpershoek E, van Kemenade F, Franssen G, de Herder W, Feelders R, Hofland L. Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene. J Clin Endocrinol Metab. 2016;101:4574–84.PubMedPubMedCentralCrossRef
29.
Cosentini D, Badalamenti G, Grisanti S, Basile V, Rapa I, Cerri S, Spallanzani A, Perotti P, Musso E, Laganà M. Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol. 2019;181:681–9.PubMedCrossRef
30.
De Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin P-F, Baudin E. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90:1819–29.PubMedCrossRef
31.
Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–35.PubMedCrossRef
32.
Lerario AM, Worden FP, Ramm CA, Hasseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014;5:232–9.PubMedPubMedCentralCrossRef
33.
34.
Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, De Bono JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010;65:765–73.PubMedCrossRef
35.
Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller H-H. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495–503.PubMedCrossRef
36.
Hernando S, Garcia-Donas J, Climent M. Phase II study of dovitinib in first line metastatic or (NON RESECTABLE PRIMARY) adrenocortical carcinoma (ACC). Sogug Study 2011–03. Annal Oncol. 2012;23:ix293.CrossRef
37.
O’Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99:1291–7.PubMedPubMedCentralCrossRef
38.
Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. 2020;105:1461–8.PubMedPubMedCentralCrossRef
39.
• Campbell M, Jimenez C, Long J, Varghese J, Shah A, Zhang M, Tamsen G, Habra M. 1MO An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma. Annals of Oncology. 2022;33:S545.This trial suggests that cabozantinib has antitumor activity (11% of response rate and 7.2 months of median PFS) in patients with ACC where other TKIs have shown dissapointing outcomes.
40.
LaPensee CR, Mann JE, Rainey WE, Crudo V, Hunt SW III, Hammer GD. ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs. Endocrinology. 2016;157:1775–88.PubMedCrossRef
41.
Smith DC, Kroiss M, Kebebew E, Habra MA, Chugh R, Schneider BJ, Fassnacht M, Jafarinasabian P, Ijzerman MM, Lin VH. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020;38:1421–9.PubMedCrossRef
42.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EE, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H. Eganelisib, a first-in-class PI3Kγ inhibitor, in patients with advanced solid tumors: results of the phase 1/1b MARIO-1 trial. Clin Cancer Res. 2023;29:2210–9.PubMedPubMedCentralCrossRef
43.
Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 1995;129:1617–28.PubMedCrossRef
44.
Demeure MJ, Armaghany T, Ejadi S, Ramanathan RK, Elfiky A, Strosberg JR, Smith DC, Whitsett T, Liang WS, Sekar S. A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC). 2016.
45.
Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015;3:1–8.CrossRef
46.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7:1–9.CrossRef
47.
•• Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RK, Capanu M, Zamarin D, Saltz LB, Ariyan CE. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol. 2020;38:71.This study showed that pembolizumab is safe and displays promising activity in patients with advanced ACC.PubMedCrossRef
48.
Carneiro BA, Konda B, Costa RB, Costa RL, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J Clin Endocrinol Metab. 2019;104:6193–200.PubMedCrossRef
49.
50.
Klein O, Senko C, Carlino MS, Markman B, Jackett L, Gao B, Lum C, Kee D, Behren A, Palmer J. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. Oncoimmunology. 2021;10:1908771.PubMedPubMedCentralCrossRef
51.
McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021;127:840–9.PubMedCrossRef
52.
Georgantzoglou N, Kokkali S, Tsourouflis G, Theocharis S. Tumor microenvironment in adrenocortical carcinoma: barrier to immunotherapy success? Cancers. 2021;13:1798.PubMedPubMedCentralCrossRef
53.
Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020;8:e001009.PubMedPubMedCentralCrossRef
54.
• Castillon JC, Molina-Cerrillo J, Viñuales MB, Garcia-Carbonero R, Teule A, Custodio A, Jimenez-Fonseca P, López C, Hierro C, Carmona-Bayonas A. 723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: a multi-cohort basket phase II trial (CABATEN/GETNE-T1914). Ann Oncol. 2023;34:S498.This is the first report of among prospective clinical trials where VEGFR TKI plus immunotherapy combination was evaluated in ACC, and abozantinib plus atezolizumab in 24 patients with refractory ACC showed response rate of 8.5%.CrossRef
Metadata
Title
Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma
Authors
Chulkue Pak
Shinkyo Yoon
Jae Lyun Lee
Tak Yun
Inkeun Park
Publication date
21-02-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01510-z

Other articles of this Issue 4/2024

Current Oncology Reports 4/2024 Go to the issue

REVIEW

Integrated care in breast cancer

REVIEW

Metronomic Chemotherapy in Elderly Patients

REVIEW

Update on the management of bone metastases

REVIEW

Head and Neck Mucosal Melanoma: Where Are We Now?

REVIEW

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry

REVIEW

Lymph node dissection in testicular cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits